Livanova

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LivaNova reports solid Q4 earnings, eyes growth amidst industry challenges

LivaNova's Q4 2022 showcased revenue growth and operational resilience amid challenges. With a strong cash position and strategic focus, the company aims for continued growth in 2023. Managing inflation, supply chain issues, and debt levels will be crucial for sustained success.

Livanova reports robust Q1 earnings, eyes growth amid market recovery

Livanova's Q1 2023 showcased strong revenue growth driven by Cardiopulmonary and Neuromodulation segments, with strategic initiatives progressing well.
While facing challenges in ACS revenue and epilepsy monitoring trends, the company remains focused on patient care and innovation.
Opportunities lie in market recovery, international business growth, and continued progress in strategic initiatives for future expansion.
Overall, Livanova's performance reflects resilience, adaptability, and a commitment to driving shareholder value creation.

LivaNova reports strong Q2 revenue growth and strategic initiatives progress

LivaNova's Q2 2023 earnings call highlighted robust revenue growth, improved margins, and strategic initiatives driving positive momentum. While facing legal challenges and patient access issues, the company is investing in core business growth and innovation for future opportunities.

LivaNova reports strong Q3 results, eyes growth amid leadership transition

LivaNova's Q3 2023 performance showcased revenue growth, margin expansion, and increased earnings per share, underpinned by operational efficiency.
While facing challenges in cost management and leadership transition, the company is poised for growth with opportunities in segment performance and margin improvement.
Increased guidance for full-year 2023 reflects confidence in future prospects, with a focus on product launches and clinical study progress.
Anticipated tax rate changes and the need for successful volume scaling present considerations for future financial planning and operational execution.

LivaNova reports strong Q4 growth, eyes revenue expansion in 2024

LivaNova's Q4 2023 performance showed revenue growth, margin impact from cybersecurity incident, and positive guidance for 2024.
The company's strengths lie in segment reorganization, income improvement prospects, and strategic focus on growth areas.
Challenges include cybersecurity disruptions, legal uncertainties, tax rate fluctuations, and unaccounted stock-based compensation impacts.
Opportunities in revenue growth, product expansion, international market penetration, and strategic planning with new leadership are key focus areas.

LivaNova reports robust Q1 earnings, eyes growth through innovation

LivaNova's Q1 performance reflects a solid start to 2024, driven by revenue growth and strong financial metrics. The company's strategic focus on innovation, clinical studies, and disciplined growth strategies positions it well for future success in the healthcare market.

LivaNova reports strong Q2 earnings, eyes growth through strategic focus

LivaNova's Q2 2024 earnings call highlighted robust financial performance, strategic imperatives, and revised guidance. The company aims to capitalize on its strengths in cardiopulmonary and epilepsy businesses while addressing challenges in litigation and expenses. Opportunities for growth are evident through revised guidance and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

LivaNova PLC (LIVN) CEO Damien McDonald on Q1 2019 Results - Earnings Call Transcript

These stocks lost ground even as the broader market posted solid gains.

Why LivaNova Slumped Today

The medical-device company posted tepid preliminary first-quarter revenue.

Here's Why LivaNova Plummeted Today

News for Livanova Stock (LIVN)